TrialLeukemia2016

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

G Barosi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.